3SBio (STU:83B) Other Current Liabilities: €207 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:83B 3SBio Inc STU:83B
89 GF Score
Price €1.85
GF Value €1.44
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Other Current Liabilities?

3SBio STU:83B -1.43% 89 Other Current Liabilities is €207 Mil as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 89/100 and a GF Value™ of €1.44 (Modestly Overvalued). The stock has 1 warning sign investors should review.

3SBio's other current liabilities for the quarter that ended in Dec. 2025 was €207 Mil.

3SBio's quarterly other current liabilities declined from Dec. 2024 (€152 Mil) to Jun. 2025 (€145 Mil) but then increased from Jun. 2025 (€145 Mil) to Dec. 2025 (€207 Mil).

3SBio's annual other current liabilities increased from Dec. 2023 (€127 Mil) to Dec. 2024 (€152 Mil) and increased from Dec. 2024 (€152 Mil) to Dec. 2025 (€207 Mil).

3SBio Other Current Liabilities Related Terms

3SBio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for 3SBio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio Other Current Liabilities Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.49 105.20 127.41 152.20 207.24

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.41 125.73 152.20 145.10 207.24
STU:83B
89GF Score
3SBio Inc STU:83B
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €207 Mil mean?
3SBio (STU:83B) has a Other Current Liabilities of €207 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on 3SBio.
Is 3SBio's Other Current Liabilities too high?
3SBio's current Other Current Liabilities is €207 Mil. Overall, 3SBio has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Other Current Liabilities compare to VRTX and REGN?
3SBio's Other Current Liabilities of €207 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on 3SBio. 3SBio's current Other Current Liabilities is €207 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.44, compared to a current price of €1.85 — trading 28.5% above its estimated fair value. The current Other Current Liabilities is €207 Mil. 3SBio's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For 3SBio (STU:83B), the current Other Current Liabilities is €207 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.85 is trading 28.5% above its estimated GF Value™ of €1.44. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for STU:83B:

  • Other Current Liabilities: €207 Mil
  • GF Value™: €1.44 vs. price of €1.85 (28.5% above fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score

Get the complete analysis for STU:83B

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price
€1.44
GF Value